CervoMed to Present at the Emerging Growth Conference

BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present at the Emerging Growth Conference, being held virtually on Wednesday, October 22, 2025.

Presentation Details
Format: Corporate Presentation
Date: Wednesday, October 22, 2025
Time: 11:25 – 11:55 AM ET
Webcast Link: https://goto.webcasts.com/starthere.jsp?ei=1717092&tp_key=1ddfafa563&sti=crvo

The webcast and replay of the presentation will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.

About CervoMed
CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. The Company’s recently completed Phase 2b trial evaluated neflamapimod in patients with DLB.

Investor Contact:
PJ Kelleher
LifeSci Advisors
[email protected]
617-430-7579

You May Also Be Interested In

• Gold Exchange Universe Launches Portal Version 24k — Sydney’s Precious Metal Buyers for Scrap Gold, Gold Bullion and Jewellery, Paying Close to 98% of Spot
• New Plaistow HQ Positions Bradford Constrution to Build ADUs Across Two States
• The Taiwan Freedom Project Will Uphold a Free and Open Indo-Pacific by Winning in the Information Domain